Skip directly to page options Skip directly to A-Z link
Volume 29, Number 11—November 2023
Synopsis

Outbreak of Pandoraea commovens Infections among Non–Cystic Fibrosis Intensive Care Patients, Germany, 2019–2021

Tassilo KruisComments to Author , Peter Menzel, Rolf Schwarzer, Solveigh Wiesener, Felix Schoenrath, Frank Klefisch, Miriam Stegemann, and Frieder Pfäfflin
Author affiliations: Labor Berlin Charité Vivantes GmbH, Berlin, Germany (T. Kruis, P. Menzel, R. Schwarzer); German Heart Center Berlin, Berlin (S. Wiesener, F. Schoenrath); Paulinenkrankenhaus, Berlin (F. Klefisch); Charité–Universitätsmedizin Berlin, Berlin (M. Stegemann, F. Pfäfflin)

Main Article

Table 3

Antimicrobial susceptibilities of Pandoraea commovens isolates in an outbreak among non–cystic fibrosis intensive care patients, Germany, 2019–2021

Antimicrobial drugs tested MIC, mg/L Breakpoints, mg/L
Susceptible Resistant
Ampicillin
 >32
 <2
 >8
Ampicillin/sulbactam
 <2
 <2
 >8
Piperacillin
 8 to >128
 <8
 >16
Piperacillin/tazobactam
 <1 to >128
 <8
 >16
Temocillin
 >128
 IE
 IE
Cefotaxime
 8–16
 <1
 >2
Ceftazidime
 >64
 <4
 >8
Cefepime
 >64
 <4
 >8
Ceftolozane/tazobactam
 16 to >256
 <4
 >4
Ceftazidime/avibactam
 16 to >256
 <4
 >8
Cefiderocol
 >256
 <2
 >2
Meropenem
 1–8
 <2
 >8
Imipenem
 <0.25 to 1
 <2
 >4
Imipenem/relebactam
 <1
 <2
 >2
Ertapenem
 <0.5 to >8
 <0.5
 >0.5
Aztreonam
 32 to >128
 <4
 >8
Aztreonam/avibactam
 >128
 NA
 NA
Ciprofloxacin
 >4
 <0.25
 >0.5
Moxifloxacin
 >8
 <0.25
 >0.25
Gentamicin
 8 to >16
 <0.5
 >0.5
Tobramycin
 >16
 <0.5
 >0.5
Amikacin
 >64
 1
 >1
TMP/SXT
 <20
 IE
 IE
Fosfomycin
 128 to >256
 IE
 IE
Colistin
 >16
 IE
 IE
Minocycline
 1–4
 IE
 IE
Tigecycline
 1
 <0.5
 >0.5
Doxycycline >16 IE IE

*MIC results are from susceptibility testing of 35 Pandoraea spp. isolates. The table comprises results of different test methods VITEK 2 (bioMérieux, https://www.biomerieux.com), MICRONAUT-S broth microdilution (MERLIN Diagnostika GmbH, https://www.merlin-diagnostika.de), and MIC strips (Liofilchem, https://www.liofilchem.com). IE, insufficient evidence, no breakpoints available; NA, not applicable; TMP/SXT, trimethoprim/sulfamethoxazole. †According to pharmacokinetic/pharmacodynamic (non–species related breakpoints from European Committee on Antimicrobial Susceptibility Testing Clinical Breakpoint Tables version 11.0, 2021 (http://www.eucast.org).

Main Article

Page created: October 03, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external